<< Vivakor's shareholders to receive stock dividend of HealthAmerica | NIH director to speak on new horizons for human health in biomedical research >>

Investigators to discuss data presentations on carfilzomib inhibitor at ASH Annual Meeting

Published on December 5, 2009 at 5:49 AM · No Comments

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host an investor teleconference and webcast. Principal investigators will discuss the data presentations surrounding carfilzomib in relapsed and/or refractory multiple myeloma, as featured at the 51st American Society of Hematology (ASH) Annual Meeting.

The teleconference will begin at 9:00 a.m. CT/10:00 a.m. ET on Monday, December 7, 2009. The live webcast will be available at:

SOURCE Onyx Pharmaceuticals, Inc.

de1c895a-1349-44a5-bdf0-0a466cbb2d7b|0|.0

Posted in: Drug Trial News

Tags: Cancer, Hematology, Kidney Cancer, Liver Cancer, Multiple Myeloma, Myeloma, Nexavar, Sorafenib

Scripps Research receives NIH grant to determine how HCV induces liver cancerThe Scripps Research Institute has been awarded a $2.2 million grant by the National Institutes of H...
FDA accepts SGEN's brentuximab vedotin BLAs for Hodgkin lymphoma, ALCL treatmentSeattle Genetics, Inc. announced today that the U.S. Food and Drug Administration has accepted for f...
Human Genome Sciences second-quarter revenues increase to $38.8 millionHuman Genome Sciences, Inc. today announced financial results for the quarter ended June 30, 2010, a...
Samsung Medical Center, Pfizer form research partnershipSamsung Medical Center and the world's leading bio-pharmaceutical company Pfizer Inc. announced that...
Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drugAEterna Zentaris Inc., ("the Company") a global biopharmaceutical company focused on endocrine thera...
Research reveals new protective properties of vitamin CResearchers at the University of Leicester and Institute for Molecular and Cellular Biology in Portu...
$11.5 million grant to Mayo Clinic Cancer Center to translate research into treatments for women with ovarian cancerInvestigators at the Mayo Clinic Cancer Center have received a five-year, $11.5 million grant to tra...
Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancerOncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.